Cargando…

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

OBJECTIVES: To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. METHODS: Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2, 3 and 4 and every 4 weeks thereafter. Placebo-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Rahman, Proton, Gottlieb, Alice B, Kirkham, Bruce, Kajekar, Radhika, Delicha, Eumorphia-Maria, Pricop, Luminita, Mpofu, Shephard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850284/ https://www.ncbi.nlm.nih.gov/pubmed/28968735 http://dx.doi.org/10.1093/rheumatology/kex301

Ejemplares similares

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
por: Nash, Peter, et al.
Publicado: (2018)

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
por: Mease, Philip J, et al.
Publicado: (2021)

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study
por: Mease, Philip J., et al.
Publicado: (2019)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
por: McInnes, Iain B., et al.
Publicado: (2018)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
por: Mease, Philip J, et al.
Publicado: (2018)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
por: Mease, Philip, et al.
Publicado: (2018)

Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
por: Mease, Philip, et al.
Publicado: (2022)

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
por: Schreiber, Stefan, et al.
Publicado: (2019)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
por: GOTTLIEB, Alice B., et al.
Publicado: (2022)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
por: Deodhar, A., et al.
Publicado: (2019)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study
por: Gottlieb, A.B., et al.
Publicado: (2021)

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2015)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
por: Ritchlin, Christopher, et al.
Publicado: (2014)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
por: Kivitz, Alan J., et al.
Publicado: (2019)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
por: Coates, Laura C., et al.
Publicado: (2022)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ldnpjlcjsk7f4g5c8vebojh6to